NeuroSense (NRSN) director Pellizzari details option and share holdings

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. director Christine A. Pellizzari filed an initial ownership report showing existing equity interests rather than new trades. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable. It also discloses direct holdings of Ordinary Shares, including restricted shares that vest on December 30, 2026 and January 30, 2027, subject to continued service and achievement of specified business milestones.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Pellizzari Christine A

Role Director

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 72,000 shares (Direct); Ordinary Shares — 48,000 shares (Direct)

Footnotes (1)

1. These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. These options are fully vested and exercisable.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pellizzari Christine A

(Last) (First) (Middle)

C/O NEUROSENSE THERAPEUTICS LTD.

11 HAMENOFIM STREET, BUILDING B

(Street)

HERZLIYA 4672562

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NeuroSense Therapeutics Ltd. [ NRSN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	48,000	D
Ordinary Shares(1)	60,000(1)	D
Ordinary Shares(2)	99,898(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(3)	03/10/2023	03/10/2032	Ordinary Shares	72,000(3)	$1.43	D

Explanation of Responses:

1. These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

2. These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

3. These options are fully vested and exercisable.

	/s/ Christine Pellizzari	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the NeuroSense (NRSN) Form 3 filing by Christine Pellizzari show?

The Form 3 shows director Christine A. Pellizzari’s existing equity holdings in NeuroSense. It lists vested stock options and Ordinary Shares, including restricted shares that vest over time if service and business milestone conditions are met.

How many NeuroSense (NRSN) options does Christine Pellizzari report on Form 3?

Christine A. Pellizzari reports options to purchase 72,000 NeuroSense Ordinary Shares. These options have a $1.43 exercise price per share, are fully vested and exercisable, and expire on March 10, 2032, reflecting a long-dated incentive position.

Are any of Christine Pellizzari’s NeuroSense (NRSN) shares restricted?

Yes. The filing notes restricted Ordinary Shares that vest on December 30, 2026 and January 30, 2027. Vesting requires continued service and achievement of specified business milestones under the restricted share agreements.

Does the NeuroSense (NRSN) Form 3 indicate insider buying or selling?

No insider buying or selling is indicated. The entries are classified as holdings, and the transaction summary shows no buy or sell activity. The Form 3 primarily establishes Pellizzari’s initial ownership position as a director.

What is the significance of the vesting milestones in NeuroSense (NRSN) Form 3?

The vesting milestones tie restricted share vesting to performance. Shares vest only if Christine A. Pellizzari remains in service through 2026/2027 and NeuroSense achieves specified business milestones outlined in the restricted share agreements.